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FoxO3 increases miR-34a to cause palmitate-induced
cholangiocyte lipoapoptosis
Sathish Kumar Natarajan,1,2 Bailey A. Stringham, Ashley M. Mohr, Cody J. Wehrkamp, Sizhao Lu,
Mary Anne Phillippi, Dee Harrison-Findik, and Justin L. Mott
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha NE

Abstract Nonalcoholic steatohepatitis (NASH) patients have
elevated plasma saturated free fatty acid levels. These toxic
fatty acids can induce liver cell death and our recent results
demonstrated that the biliary epithelium may be susceptible
to lipotoxicity. Here, we explored the molecular mechanisms of cholangiocyte lipoapoptosis in cell culture and in an
animal model of NASH. Treatment of cholangiocytes with
palmitate (PA) showed increased caspase 3/7 activity and increased levels of cleaved poly (ADP-ribose) polymerase and
cleaved caspase 3, demonstrating cholangiocyte lipoapoptosis. Interestingly, treatment with PA significantly increased
the levels of microRNA miR-34a, a pro-apoptotic microRNA
known to be elevated in NASH. PA induction of miR-34a was
abolished in cholangiocytes transduced with forkhead family
of transcription factor class O (FoxO)3 shRNA, demonstrating that FoxO3 activation is upstream of miR-34a and suggesting that FoxO3 is a novel transcriptional regulator of
miR-34a. Further, anti-miR-34a protected cholangiocytes
from PA-induced lipoapoptosis. Direct and indirect targets
of miR-34a, such as SIRT1, receptor tyrosine kinase (MET),
Kruppel-like factor 4, fibroblast growth factor receptor
(FGFR)1, and FGFR4, were all decreased in PA-treated cholangiocytes. SIRT1 and MET were partially rescued by a miR34a antagonist. Cholangiocyte apoptosis and miR-34a were
dramatically increased in the liver of mice with early histologic features of NASH. Our study provides evidence for
the pro-apoptotic role of miR-34a in PA-induced cholangiocyte lipoapoptosis in culture and in the liver.—Natarajan,
S. K., B. A. Stringham, A. M. Mohr, C. J. Wehrkamp, S. Lu,
M. A. Phillippi, D. Harrison-Findik, and J. L. Mott. FoxO3
increases miR-34a to cause palmitate-induced cholangiocyte
lipoapoptosis. J. Lipid Res. 2017. 58: 866–875.
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The incidence of nonalcoholic fatty liver disease (NAFLD)
is skyrocketing in both developed and developing countries due, in large part, to the increased prevalence of
obesity. NAFLD is the hepatic manifestation of metabolic
syndrome and is accompanied by increased FFAs in circulation. These increased free fatty acids (FFAs) are due to excessive adipose tissue lipolysis and are toxic to cells in the
liver, heart, and pancreas (1, 2). Hepatocyte lipoapoptosis
due to increased circulating FFAs is recognized as a hallmark of nonalcoholic steatohepatitis (NASH), a severe
form of NAFLD. In addition to hepatocyte injury, cholestatic
NAFLD has been suggested to develop at least in a subset of
patients with NAFLD (3). In support of this notion, we have
recently demonstrated that biliary epithelial cells, or cholangiocytes, undergo lipoapoptosis upon saturated FFA
exposure. Saturated FFAs triggered activation of stress kinases, like p38 and ERK. We also found that FFA-induced
cholangiocyte lipoapoptosis was dependent on the forkhead family of transcription factor class O (FoxO)3, and, in
part, its downstream target, p53-upregulated modulator of
apoptosis (PUMA) (4, 5).
MicroRNAs are noncoding small RNAs that mediate
posttranscriptional regulation of mRNA transcript levels
and protein translation. They have been shown to play an
important role in a variety of cellular processes, including apoptosis. In particular, miR-34a is a pro-apoptotic
microRNA that decreases expression of several cell survival
proteins (6–9). Additionally, miR-34a expression is induced
by p53 at the promoter level to increase apoptosis (10, 11).
miR-34a has been suggested to modulate apoptosis through
the SIRT1/p53 pathway (9, 12, 13). NAFLD and NASH
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receptor tyrosine kinase; NAFLD, nonalcoholic fatty liver disease; NASH,
nonalcoholic steatohepatitis; PA, palmitate; PARP, poly (ADP-ribose)
polymerase, PUMA, p53-upregulated modulator of apoptosis; UDCA,
ursodeoxycholic acid.
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patients have elevated levels of pro-apoptotic miR-34a in
the circulation and the liver. Increased miR-34a levels were
also shown to be associated with the severity of NASH in
patients (14, 15). However, the exact role for miR-34a in
cholangiocyte lipoapoptosis is unknown.
In the present study, we hypothesized that miR-34a is important in cholangiocyte lipoapoptosis. We explored the
critical role for miR-34a during cholangiocyte lipoapoptosis induced by palmitate (PA). Treatment of cholangiocytes
with PA induced the expression of miR-34a, reduced expression of several miR-34a target proteins, and increased
lipoapoptosis. We also identified miR-34a as a novel target
of FoxO3.

MATERIALS AND METHODS
Materials

Vehicle treatment was isopropanol with a final concentration
of 1% in the medium. The SIRT1 inhibitor, EX527, was used at
100 M and the receptor tyrosine kinase (MET) inhibitor, Su11274,
was used at 2 M.

Measurement of apoptosis
Percent apoptosis was quantified by characteristic nuclear morphology visualized by treatment with DNA-binding dye, DAPI, as
described before (6, 7). Briefly, cells were stained with 5 g/ml
DAPI for 20–30 min at 37°C. Images were obtained under UV
epifluorescence microscopy using a Leica DMI6000B inverted
microscope. Apoptotic nuclei (condensed, fragmented) were
counted and presented as a percent of total nuclei. At least 100
cells were counted per well and experiments were performed in
triplicate. Caspase 3/7 activity was measured by enzymatic fluorophore release (Apo-ONE) according to the manufacturer’s instructions (Promega) and were represented as fold-change compared
with vehicle treatment, with experiments performed in quadruplicate as described (5).

Nuclear isolation and Western blot analysis

Palmitic acid (#P5585) and fatty acid-free BSA (#A3803) were
obtained from Sigma-Aldrich, St. Louis, MO. Magnetic protein G
beads (#S1430S) were purchased from New England Bio Labs,
Ipswich, MA. Trizol reagent and all other chemicals were obtained
from Thermo Fisher Scientific, Waltham, MA.

Nuclear extracts were prepared as described (17). Cell lysates
containing 30 g of protein were resolved by SDS-PAGE. Proteins
were transferred to a nitrocellulose membrane and visualized by
immunoblotting.

Animals

Lentiviral shRNA transduction

All procedures involving animals in this work were approved
by the IACUC at the University of Nebraska Medical Center.
C57BL/6J mice (4–6 weeks old) were randomly divided into two
groups and fed either control diet (17.2% kcal from fat, 100 g/kg
sucrose) or high-fat high-sucrose (HFHS) diet (42% kcal from
fat with 54% saturated and 9.7% trans-fat, 0.4% cholesterol, and
340 g/kg sucrose) for 3 months. Water was given ad libitum and
the HFHS mice were fed sucrose-containing water (40 g/l) to
mimic the Western diet, as described (16).

shRNA silencing lentiviral pLKO.1-puro vector targeting FoxO3
and control GFP were obtained from Sigma and stable transfections were carried out as described (5). FoxO3 shRNA #1 and #2
target the nucleotide sequences 2185-2205 and 1626-1648 of
FoxO3 mRNA (NM_001455.1), respectively.

Isolation and quantitation of miR-34a

Liver tissues were formalin-fixed, paraffin embedded, and
stained for Masson trichrome reaction by the Tissue Sciences core
facility at the University of Nebraska Medical Center.

Cellular RNA and total liver RNA were isolated using lysis in
chaotropic salt and acid:phenol:chloroform extraction (mirVana
kit; Life Technologies). Total RNA (100 ng) was used to amplify
miRs using hydrolysis probe and stem loop primers for miR-34a
(hsa-miR-34a-5p, #PN4427975-000426) and Z30 control RNA
(#PN4427975-001092). Relative expression was calculated using
the delta CT method.

Antibodies

miR-34a mimic and locked nucleic acid transfection

Rabbit antiserum against FoxO3 (2497), cleaved caspase 3
(C9661), and cleaved poly (ADP-ribose) polymerase (PARP)
(P9542) were from Cell Signaling. Rabbit antiserum against
PUMA (28226) was from Santa Cruz. Goat anti-lamin B (sc-6216)
and mouse anti-actin (sc-1615) were purchased from Sigma.
Peroxidase-conjugated secondary antisera were from Jackson
Immuno Research laboratory.

H69 and KMCH cells were transfected for 24 h with negative
control A, a nontargeting control locked nucleic acid (LNA) oligonucleotide, or LNA-34a (250999-B) obtained from Exiqon.
Cells were then treated with vehicle or PA (800 M) for another
24 h and apoptotic markers were measured as described above.
For miR-34a targets, cells were transfected with either miR-34a
mimic (to replicate fatty acid-induced expression) or antagonist
(LNA-34a) for 24 h followed by protein isolation.

Masson trichrome staining

Cell lines and treatment
H69, a human normal immortalized cholangiocyte cell line, was
grown in DMEM supplemented with 10% FBS, insulin (5 g/ml),
adenine (24.3 g/ml), epinephrine (1 g/ml), triiodothyroninetransferrin (triiodothyronine, 2.23 ng/ml; transferrin, 8.19 g/ml),
epidermal growth factor (9.9 ng/ml), and hydrocortisone (5.34
g/ml). KMCH, Mz-ChA-1 and HuCCT-1 (human cholangiocarcinoma cell lines), MDA-KKA2 (mouse cholangiocyte cell line),
and Huh7 (hepatoma cell line) were grown in DMEM supplemented with 10% FBS, insulin (0.5 g/ml), and G418 (50 g/ml)
(5). H69, KMCH, HuCCT, Mz-ChA-1, Huh7, and MDAKK-2 cells
were treated with the indicated concentrations of FFAs (400–800
M) dissolved fresh in isopropanol at 100× and added to prewarmed medium containing 1% fatty acid-free BSA for 24 h.

Statistics
Data are expressed as mean ± SEM. Statistical analysis was performed using one-way ANOVA with Bonferroni post hoc correction. P < 0.05 was considered to be statistically significant.

RESULTS
Evidence for PA-induced cholangiocyte lipoapoptosis
Our earlier report had established that cholangiocytes
undergo lipoapoptosis upon FFA exposure (5). We treated
normal immortalized and malignant cholangiocytes with
Role of miR-34a in cholangiocyte lipoapoptosis
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PA (800 M) for 24 h and measured caspase 3/7 activation. H69 cells showed a 10-fold increase in caspase 3/7
activity with PA treatment compared with vehicle (Fig. 1A).
Cholangiocyte cell lines, HuCCT, KMCH, and Mz-ChA-1,
showed a 20-fold, 9-fold, and 8-fold increase in caspase 3/7
activity, respectively, with PA treatment compared with vehicle (Fig. 1B–D). We tested PA concentrations from 0 to
800 M and found increased apoptosis in KMCH cells over
400 M (Fig. 1E) or over 200 M in Mz-ChA-1 cells (Fig.
1F). In addition to caspase activation, we assessed the caspase cleavage products, PARP and caspase 3 itself. PARP is
a 116 kDa protein with a role in DNA repair, chromatin
structure formation, and differentiation. Increased caspase
3/7 activity with PA treatment was accompanied by an increase in the levels of 85 kDa cleaved PARP and cleaved
caspase 3 in cholangiocytes (Fig. 1G). We have reported
that the pro-apoptotic protein, PUMA, a downstream target of FoxO3 was induced by PA and was partly responsible
for cholangiocyte lipoapoptosis (5). Here, we tested the
expression of PUMA with PA treatment in different cholangiocyte cell lines and found that the expression was
increased in H69, HuCCT, KMCH, and Mz-ChA-1 cells
treated with PA compared with cells treated with vehicle
(Fig. 1H). These results suggest that treatment with PA,
comparable to pathophysiological levels found in NASH
patients, induced cholangiocyte lipoapoptosis.

PA induced miR-34a expression
To further evaluate the mechanism of cholangiocyte lipoapoptosis, we tested the role of the pro-apoptotic microRNA,
miR-34a, in cholangiocyte lipoapoptosis. miR-34a was chosen because it was elevated in the liver and circulation from
patients with NASH or diabetes (14, 15, 18). We analyzed
miR-34a expression upon exposure to a lower concentration of PA (400 M instead of 800 M). We know that 400–
800 M PA induces a concentration-dependent increase in
cell death (5), so initially we chose the lower concentration
to minimize RNA loss from apoptosis. We found that miR34a levels were significantly increased in human cholangiocyte cell lines, H69, Mz-ChA-1, KMCH, and HuCCT, treated
with 400 M PA (Fig. 2A–D). To test the generality of our
finding, we used a mouse cholangiocyte cell line, MDAKKA2. PA treatment showed an increase in miR-34a expression relative to vehicle-treated MDA-KKA2 cells (Fig.
2E). We next tested to determine whether PA also induced
an increase in miR-34a expression in hepatocytes. A hepatoma cell line, Huh7, was treated with 400 M PA for 24 h
and miR-34a expression levels were measured. Similar to
cholangiocytes, we observed that PA treatment induced expression of miR-34a in this hepatocyte-derived cell line
(Fig. 2F). PA treatment of KMCH cells at 400, 600, or 800
M progressively increased miR-34a levels (Fig. 2G). Together, these results suggest that PA induces the expression

Fig. 1. PA induced cholangiocyte lipoapoptosis. Cell
lines were treated with PA (800 M) or vehicle (Veh)
for 24 h. A–D: Caspase 3/7 activity was significantly increased in PA-treated cells. Data represent the mean ±
SEM for n = 4. *P < 0.05, compared with vehicle by ttest. KMCH cells (E) and Mz-ChA-1 cells (F) treated
with PA (0–800 M) showed a significant concentration-dependent increase in caspase 3/7 activity. Data
represent the mean ± SEM for n = 4. ***P < 0.05, compared with vehicle; statistical comparison was by
ANOVA with post hoc correction. G: Cleaved PARP
and cleaved caspase 3 levels were increased in wholecell lysates taken from PA-treated cells compared with
vehicle-treated (V) cells. H: PUMA protein was also
increased by PA treatment.
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activity with PA treatment (Fig. 3A). Similarly, anti-miR-34a
transfected KMCH cells showed a significant decrease in
PA-induced cholangiocyte lipoapoptosis (Fig. 3B). These
results suggest an important role for miR-34a in PA-induced
cholangiocyte lipoapoptosis.
FoxO3 is critical for miR-34a expression
Our earlier report demonstrated a critical role of FoxO3
in cholangiocyte lipoapoptosis (5). Here, we tested to determine whether FoxO3 is required for the induction of
miR-34a during PA lipotoxicity. PA-treated H69 and KMCH
cells showed an increase in nuclear FoxO3 levels after 16 h
(Fig. 4A). Transduction with FoxO3 shRNA in H69 and
KMCH cells resulted in knockdown of FoxO3 protein, as
compared with control GFP shRNA transduced cells (Fig.
4B, C). Control shRNA- and FoxO3 shRNA-transduced
cells were treated with 600 M PA or vehicle for 24 h and
miR-34a levels were analyzed by quantitative RT-PCR. PA
significantly induced the expression of miR-34a in H69
cells transduced with control shRNA. However, increased
miR-34a expression due to PA treatment was abolished
in FoxO3 shRNA-transduced cells (Fig. 4D). Similarly, the
induction of miR-34a by PA was significantly abrogated in
KMCH cells transduced with FoxO3 shRNA (Fig. 4E).
These data suggest that FoxO3 is a novel transcriptional
regulator of miR-34a.

Fig. 2. Induction of miR-34a by PA. A–F: Cell lines (cholangiocyte- or cholangiocarcinoma-derived: H69, Mz-ChA-1, KMCH,
HuCCT, and MDA-KKA2; hepatoma-derived: Huh7) were treated
with PA (400 M) or vehicle (Veh) for 24 h. This lower concentration was chosen to limit cell death from PA allowing reliable RNA
isolation. Relative expression of pro-apoptotic miR-34a was significantly elevated in PA-treated cholangiocytes and hepatocytes. miR34a was quantified by RT-PCR and normalized to Z30 for human
cell lines or RNU6 for mouse MDA-KKA2 cells. G: The full concentration range of PA from 200 to 800 M was tested in KMCH cells
and showed increased levels of miR-34a with an increasing concentration of PA. Data represent the mean ± SEM for n = 4. *P < 0.05,
t-test.

of miR-34a in both cholangiocytes and hepatocytes, possibly contributing to lipoapoptosis.
Anti-miR-34a protects cholangiocyte lipoapoptosis
To test the role of miR-34a in cholangiocyte lipoapoptosis, we transfected H69 and KMCH cells with antisense
LNA against miR-34a (anti-miR-34a) or negative control
before challenging with PA. Treatment with PA induced
cholangiocyte lipoapoptosis in H69 and KMCH cells transfected with negative control, as evidenced by an increase in
percent apoptotic nuclei and caspase 3/7 activity (Fig. 3).
H69 cells transfected with anti-miR-34a showed a significant decrease in percent apoptotic nuclei and caspase 3/7

miR-34a target expression
The mRNAs of SIRT1, MET, and Kruppel-like factor 4
(KLF4) comprise of noncanonical and canonical seed
binding sites for miR-34a (6, 9, 12, 13, 19–22). We then assessed expression levels of these anti-apoptotic proteins after 16 or 24 h of PA treatment. The levels of SIRT1 in H69
cells were found to be decreased after 16 or 24 h with 800
M PA treatment compared with vehicle (Fig. 5A). H69
cells also showed a decrease in MET expression after 16
and 24 h of PA treatment (Fig. 5A). Levels of KLF4 were
also lower in H69 cells treated with PA. Similarly, KMCH
and HuCCT cells showed a decrease in the expression of
SIRT1, MET, and KLF4 with 800 M of PA treatment at the
16 and 24 h time points (Fig. 5B, C). We next tested to determine whether this was also true for the Huh7 hepatocyte
cell line. Treatment with 800 M PA led to a decrease in
the expression of SIRT1 and MET, both after the 16 and
24 h time points. We did not find any expression of KLF4
in Huh7 cells and the absence of KLF4 was previously observed in proteomic studies of Huh7 cells (23, 24).
Levels of SIRT1 were decreased in Mz-ChA-1 cells after
16 or 24 h of PA treatment (Fig. 5E). -Klotho and fibroblast growth factor receptor (FGFR)1 have been shown to
be targets of miR-34a (25). Further, FGFR1 and FGFR4 are
dependent on the coreceptor, -klotho (26). Both FGFR1
and FGFR4 levels were decreased in cells exposed to PA
after 16 or 24 h of treatment (Fig. 5E). We were unable to
identify a sensitive and specific antibody to detect -klotho
protein.
Increasing PA concentrations decreased the protein levels
of SIRT1, MET, and KLF4. In Mz-ChA-1 cells, SIRT1 did
not show large expression changes (Fig. 5F), while MET
Role of miR-34a in cholangiocyte lipoapoptosis
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Fig. 3. Anti-miR-34a protected against PA-induced
cholangiocyte lipoapoptosis. A, B: miR-34a was antagonized by transfecting cells with LNA-34a (anti-miR34a; filled bars) compared with nontargeting negative
control A LNA (Neg Con; open bars). Twenty-four
hours later, cells were treated with PA (800 M) or vehicle (Veh) for 24 h. PA-induced cholangiocyte lipoapoptosis was measured by nuclear morphology (left)
and by caspase 3/7 activity (right). Data represent the
mean ± SEM for n = 4. *P < 0.001, compared with vehicle; #P < 0.001, compared with Neg Con with PA
treatment; statistical comparison was by ANOVA with
post hoc correction.

was progressively decreased with increasing the concentration of PA (Fig. 5F). In KMCH cells, increasing PA decreased SIRT1, MET, and KLF4, especially at 600–800 M
(Fig. 5G). For Fig. 5F, G, the caspase inhibitor ZVAD-FMK
was included (10 M) to limit loss of cells to lipoapoptosis.
The decrease in multiple cellular proteins was specific, as
we did not observe a decrease in actin, and observed an
increase in PUMA levels upon PA treatment. These results

suggest that miR-34a upregulation with PA treatment has
many cellular targets and decreases the levels of cell survival proteins, like SIRT1, MET, KLF4, FGFR1, and FGFR4,
potentially contributing to cholangiocyte lipoapoptosis.
miR-34a target validation
We next wanted to further validate miR-34a targets by
transfecting miR-34a mimic and anti-miR-34a in Mz-ChA-1

Fig. 4. FoxO3 induced miR-34a expression. A: Nuclear extracts were prepared from H69 or KMCH cells
treated with vehicle (Veh) or PA for 24 h. FoxO3 and
lamin B were detected by immunoblot. B, C: Cell lines
(H69 or KMCH) were transduced with shRNA to GFP
or FoxO3 (two shRNAs, indicated as #1 or #2) and
stably-transfected cells selected by antibiotic resistance.
Whole-cell FoxO3 protein levels were compared with
actin. D, E: GFP shRNA- or FoxO3 shRNA-transduced
cells were treated with PA (600 M; filled bars) or vehicle (Veh; open bars) for 24 h. miR-34a levels were
normalized to Z30. Data represent the mean ± SEM
for n = 4. *P < 0.05, compared with vehicle; #P < 0.05
compared with PA-treated GFP shRNA cells; ANOVA
with post hoc correction.
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Fig. 5. PA decreased SIRT1, MET, and KLF4. A–D: Cells were
treated with PA (800 M) or vehicle (V) for 16 or 24 h. SIRT1, MET,
and KLF4 protein expression was detected by immunoblot, compared with actin control. E: Cells were treated as in (A–D) and
SIRT1, FGFR1, or FGFR4 was detected by immunoblot compared
with actin control. F, G: Increasing PA (400, 600, or 800 M) was
added to Mz-ChA-1 or KMCH cells and SIRT1, MET, and KLF4 proteins were measured by immunoblot.

and KMCH cells. The miR-34a LNA antagonist decreased
miR-34a expression by approximately 91% in Mz-ChA-1
cells (Fig. 6A). The miR-34a mimic decreased the expression of SIRT1, MET, and KLF4 in Mz-ChA-1 cells compared
to negative-control transfected cells (Fig. 6B). Cells transfected with anti-miR-34a did not have dramatically altered
levels of these proteins (Fig. 6B). KMCH cells transfected
with miR-34a mimic showed a similar decrease in SIRT1,
MET, and KLF4 (Fig. 6B). When cells were transfected with
LNA-34a followed by PA treatment (800 M), the miR-34a
antagonist partially prevented loss of SIRT1 and MET (Fig.
6C, D). To test whether loss of function of either of these
proteins contributes to lipoapoptosis, we treated KMCH
cells with the SIRT1 inhibitor, EX527, or the MET kinase
inhibitor, Su11274, followed by 400 M PA. The lower PA
concentration was chosen to allow for detection of sensitization to PA. The SIRT1 inhibitor, either alone or in combination, increased lipoapoptosis, while the MET inhibitor
did not alter caspase 3/7 activation (Fig. 6E). Together,
cells transfected with miR-34a mimic to increase miR-34a
in the absence of PA treatment showed a decrease in predicted target proteins, such as SIRT1, MET, and KLF4. Antagonism of miR-34a partially protected from this loss,

Fig. 6. miR-34a decreased SIRT1, MET, and KLF4 protein expression. A: LNA-34a decreased miR-34a levels by 91% in Mz-ChA-1 cells
24 h after transfection. B: Mz-ChA-1 or KMCH cells were transfected
with negative control A LNA (Neg Con), microRNA mimic (miR34a), or anti-miR-34a (LNA-34a) for 24 h. SIRT1, MET, and KLF4
expression was detected by immunoblot in whole-cell lysates. C, D:
SIRT1 and MET loss in response to PA was measured in cells transfected with negative control A LNA (Neg Con) or miR-34a antagonist (LNA-34a). E: Lipoapoptosis in response to a low PA stimulus
was tested in the presence of DMSO vehicle, Su11274 MET inhibitor (2 M), EX527 SIRT1 inhibitor (100 M), or both inhibitors.
Apoptosis was assessed by caspase 3/7 activity. **P < 0.01; t-test in
(A), ANOVA with Bonferroni post hoc correction in (E).

while inhibition of SIRT1 plus PA treatment exacerbated
cell death.
Cholangiocyte lipoapoptosis in HFHS-fed mice
C57BL/6 mice were fed with control or HFHS diet for
3 months. Liver sections were analyzed with Masson trichrome
staining for the detection of chicken-wire-like collagen accumulation. Liver sections obtained from HFHS-fed mice
showed lipid droplet and collagen accumulation compared
with control-fed mice (Fig. 7A). We isolated liver total RNA
and found that miR-34a levels were significantly upregulated in HFHS diet-fed mice compared with controls (Fig.
7B). Next, we co-stained formalin-fixed liver sections with
pan-keratin (a bile duct marker) and TUNEL for the quantitation of apoptotic cholangiocytes. We observed elevated
cholangiocyte lipoapoptosis in HFHS-fed mice (Fig. 7C).
Our data provide evidence for the upregulation of hepatic
Role of miR-34a in cholangiocyte lipoapoptosis
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Fig. 7. Cholangiocyte lipoapoptosis in animal model
of NASH. A: A Masson trichrome-stained liver section
from HFHS-fed mice showed enhanced lipid droplet
and collagen accumulation compared with chow-fed
control (Con) mice. B: Total RNA was isolated from
flash-frozen liver tissue and miR-34a levels were measured relative to RNU6. C: Cholangiocytes were identified by pan-keratin staining and apoptotic nuclei were
identified in the same section by TUNEL reaction.
TUNEL-positive cholangiocytes are indicated as a percentage of total cholangiocyte nuclei. A total of 900–
3,000 cholangiocytes were scored per sample. Data
represent the mean ± SEM for n = 4 mice for each
group. *P < 0.05, t-test.

miR-34a and for cholangiocyte lipoapoptosis in an animal
model of NASH. Further, these results suggest that upregulation of miR-34a plays an important role in cholangiocyte
lipoapoptosis in a cell culture model and potentially in biliary injury during NASH.

DISCUSSION
Increased FFAs in the circulation during metabolic syndrome or NASH have fatal consequences in the liver by
inducing cholangiocyte and hepatocyte lipoapoptosis (27,
28). Increased plasma FFAs have been observed in patients with NAFLD or the associated condition of metabolic
syndrome. Plasma FFAs in 27 out of 47 NASH patients were
elevated with a mean of 752 M in NASH patients (29). De
Almeida et al. (30) showed that total plasma FFAs were 350
M in controls and 563 M in NASH patients. Further,
saturated FFA levels were 200 M in controls and 316 M
in NASH patients. Control patients similarly had 460 M
FFA levels, compared with NASH patients at 660 M (31).
Recently, Zhang et al. (32) found that control patients had
450 M plasma FFAs compared with 650 M in NAFLD
patients. Further, patients with evidence of advanced fibrosis had higher FFA levels (720 M) than patients without
evidence of advanced fibrosis (580 M). From these studies, the range for controls was 350–460 M FFAs, while
872
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patients had 563–752 M circulating FFAs. These are total
levels of all FFAs combined. In our study, we have utilized a
specific saturated FFA, PA, to reduce complexity and investigate specific signaling pathways. We chose this fatty acid
because it is the most common saturated FFA in the circulation [approximately 28% of the total FFAs (33), with a
range of 300–4,100 M in one study (34)]. Thus, our studies at 200–800 M fall within the pathologic range of FFA
concentrations.
The principal finding of this study is that PA, the predominant circulating FFA, induced cholangiocyte lipoapoptosis via FoxO3-dependent induction of pro-apoptotic
miR-34a. Our data suggest three important findings in
cholangiocyte lipoapoptosis caused due to PA exposure: 1)
PA upregulates pro-apoptotic miR-34a in a FoxO3-dependent manner to cause cholangiocyte lipoapoptosis; 2) increased miR-34a expression targets protein deacetylase
SIRT1 as well as several anti-apoptotic proteins; and 3)
cholangiocyte lipoapoptosis and miR-34a upregulation
due to lipotoxicity were also evident in an animal model of
NASH. The proposed model for FFA-induced cholangiocyte lipoapoptosis is shown in Fig. 8. These results will be
discussed in the following paragraphs.
Biliary injury and cholestatic NASH have been documented at least in a subset of patients with NAFLD (3). Our
earlier work showed implications for biliary injury in response to FFAs and demonstrated the mechanism of

Fig. 8. Schematic diagram of the proposed role of miR-34a in PAinduced cholangiocyte lipoapoptosis. The saturated FFA, PA, increased nuclear FoxO3 levels leading to increased miR-34a in
PA-treated cells. miR-34a then promoted lipoapoptosis, likely
through decreasing protein levels of its targets, SIRT1, MET, and
KLF4. Based on literature reports of SIRT1 activity on FoxO3 and
our previous finding of increased nuclear acetylated-FoxO3, we
speculate that a miR-34a-mediated decrease in SIRT1 may enhance
FoxO3 acetylation levels.

FFA-induced cholangiocyte lipoapoptosis involving the activation and nuclear translocation of FoxO3. Activation of
FoxO3 with saturated FFAs thereby increased the expression of its downstream target, PUMA, a pro-apoptotic BH3domain-containing protein, resulting in caspase-dependent
cholangiocyte lipoapoptosis (4, 5). RNAi-mediated inhibition of PUMA protected cells partially, but not completely
(5). Here, we extended our work to demonstrate the role
for pro-apoptotic miR-34a in cholangiocyte lipoapoptosis.
miR-34a has been shown to be upregulated in the liver
from patients with NASH (15). Circulating levels of miR34a were also shown to be elevated in patients with NAFLD,
NASH, diabetes, obesity, and alcoholic liver disease (18, 25,
35). In the present study, we elucidated the mechanism of
miR-34a upregulation. Our data also indicate that miR-34a
upregulation with saturated FFA is a common process for
both cholangiocyte- and hepatocyte-derived cells. Further,
transfection of an antisense oligonucleotide against miR-34a
prevented cholangiocyte lipoapoptosis due to PA exposure.
Caspase 3 activation has been suggested to lead to cleavage
of Dicer, a microRNA processing enzyme in the cytosol
(36). However, we observed a dramatic increase in mature
miR-34a levels with PA treatment in a panel of cholangiocytes tested, suggesting that Dicer is either not degraded in
lipoapoptosis or it is not limiting for microRNA processing.
We know that both cholangiocytes and hepatocytes are derived from a common progenitor cell. We observed that
miR-34a upregulation was not solely occurring in cholangiocytes, but was also seen in Huh-7 cells. The increase in
total hepatic miR-34a, either in our HFHS mice or in studies
on NASH miRs (15), is likely to be dominated by hepatocyte-derived miR-34a, as hepatocytes comprise the majority
of the cells in the liver. Whether miR-34a upregulation with
FFAs in hepatocytes occurs in a similar FoxO3-dependent
fashion, as in cholangiocytes, remains to be tested.

Our previous study implicated FoxO3 activation and
nuclear translocation in cholangiocyte lipoapoptosis (5).
We also reported that acetylated FoxO3 accumulated in
the nuclear fraction in saturated FFA-treated cells (5). We
speculated before that increased acetylation of FoxO3
might be due to a decrease in SIRT1 protein levels (5).
Loss of SIRT1 has also been shown to be associated with
insulin resistance (37, 38). Here we found that miR-34a targeted SIRT1 protein. SIRT1 is a protein deacetylase and
acetylated FoxO3 is a known SIRT1 substrate (39, 40), so
decreased SIRT1 can enhance the acetylation status of
FoxO3. Acetylated FoxO3 was shown to be pro-apoptotic in
nature and could induce downstream targets, like BIM and
PUMA. Interestingly, we found that FoxO3 is responsible
for the upregulation of miR-34a upon PA treatment. FoxO3
can increase Bcl-2 expression under normal conditions
and in alcoholic liver disease, while acetylated-FoxO3 has
been shown to have lost this protective function (41). Thus,
the increased acetylated FoxO3 in cholangiocytes exposed
to PA might have lost a Bcl-2-dependent protective function, instead becoming pro-apoptotic in nature.
Mature miR-34a has sequence complementarity to the 3′
UTR of SIRT1 mRNA. NAFLD severity in human and animal models was shown to be positively correlated with the
levels of miR-34a and inversely correlated with SIRT1 proteins levels (14). Treatment with ursodeoxycholic acid
(UDCA) prevents the upregulation of miR-34a in total liver
and primary hepatocytes (14). UDCA has been shown to
upregulate the expression of SIRT1 to deacetylate p53, a
miR-34a activator. Further, UDCA prevents posttranslational modification of p53 and reduces its transcriptional
activity (14). Our results suggest that PA-induced miR-34a
upregulation is independent of p53 transcriptional activity.
Specifically, we observed a similar increase in miR-34a levels in both normal cholangiocytes and malignant-derived
cholangiocytes that were confirmed by sequencing to have
p53 inactivating mutants (data not shown). Using an inhibitor of SIRT1, we enhanced cytotoxicity of low-dose PA,
demonstrating that loss of SIRT1 expression increased cell
injury. SIRT1 deacetylase activity has been shown to have a
role in the miR-34a promoter acetylation (9). Loss of SIRT1
results in failure of the miR-34a promoter to be deacetylated, which could possibly enhance FoxO3 transcriptional
activation of miR-34a (9). Additionally, SIRT1 can deacetylate various other transcription factors, like FXR, SREBPs,
PPARs, PGC1, LXR, FoxO1, and FoxO3 (39, 42, 43).
Deacetylation of FXR, LXR, PPARs, and PGC1 can activate their downstream targets with key roles in bile acid,
cholesterol, lipid, and energy homeostasis (44). In contrast, deacetylation of SREBP can prevent its transcriptional
activity (44). Whether these altered transcription factors
have a role in cholangiocyte lipoapoptosis needs further
investigation.
KLF4 is a zinc-finger transcription factor, tumor suppressor, and embryonic progenitor cell differentiation factor
(45). KLF4 has been shown to act as a radio-protector
against apoptotic insults (46). KLF4-deficient cells had decreased levels of the multi-domain Bcl-2 family proteins,
Mcl-1 and Bcl-XL (BCLXL) (47). Further, KLF4 was shown
Role of miR-34a in cholangiocyte lipoapoptosis
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to have transcriptional activity in the MCL1 promoter region (47). PA-induced miR-34a decreased KLF4 levels in
cholangiocyte-derived cells. Based on miR-34a regulation
of KLF4 in the literature (6), KLF4 may be performing an
anti-apoptotic role in cholangiocytes that is lost upon FFA
treatment. We also observed that MET a receptor tyrosine
kinase and hepatocyte growth factor receptor, is another
anti-apoptotic protein targeted by miR-34a that was found
to be decreased in cholangiocytes exposed to FFA. MET is
well-known to activate Akt and Stat3 cell survival pathways
(48). Additionally, the cell survival mechanism of MET also
involves sequestering Fas to block apoptosis and prevent
degradation of the anti-apoptotic regulator, FLIPL (long
splice form of FLICE inhibitor protein) (49). Normally,
FLIP binds to Fas-associated death domain, a common protein for both Fas and death receptor complexes, and forms
an apoptosis inhibitory complex that prevents the activation of pro-caspases (49). Further studies are needed to
elucidate whether loss of KLF4 or MET is critical for cholangiocyte lipoapoptosis, but a MET inhibitor did not enhance killing.
Treatment with a miR-34a inhibitor has been suggested
to be a novel therapeutic strategy for NAFLD (50). Silencing of miR-34a using a miR-34a inhibitor was shown to prevent liver injury and improve hepatic steatosis through its
target proteins, like PPAR and SIRT1, which can activate
AMP-activated protein kinase in an animal model of
NAFLD (50). Additionally, FGFR signaling promotes cell
survival (26), such that any loss of FGFR expression due to
saturated FFA, through increased miR-34a, could promote
lipoapoptosis. One of the downstream signaling pathways
of FGFRs is Akt, and miR-34a targeting of FGFRs may decrease the levels of Akt that can affect the phosphorylation
status of FoxO3 and AMP-activated protein kinase, as reported before (50). Ectopic miR-34a expression has been
shown to decrease basal Akt phosphorylation and several
proteins that regulate cell cycle that help in G1/S transition, like CKD4, CKD6, CCND1, CCNE2, and E2F3 (51).
These observations further support our hypothesis that
miR-34a is critical for cholangiocyte lipoapoptosis.
Our current and previous work demonstrates that saturated FFA induced cholangiocyte lipoapoptosis. We also
observed that increased cholangiocyte lipoapoptosis was
present in the nutrient-excess model for NASH. This model
mimics a Western diet containing high saturated fats, cholesterol, and sucrose and shows similar characteristics to
human NASH, such as ballooned hepatocytes, massive
lipid droplet accumulation, increased collagen accumulation, increased -smooth muscle actin expression, and increased pro-inflammatory cytokines in the liver. We
observed enhanced levels of miR-34a in mice fed the HFHS
diet, consistent with a role for miR-34a in the lipoapoptosis
of NASH. A recent study showed that lentiviral injection of
miR-34a inhibitor resulted in protection against liver injury
(50). We predict that treatment with a miR-34a inhibitor
might also prevent cholangiocyte lipoapoptosis. Further
studies are required to elucidate whether cholangiocyte lipoapoptosis contributes to or promotes the progression of
NASH, at least in a subset of cholestatic NAFLD patients.
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In conclusion, our results show that PA-induced cholangiocyte lipoapoptosis involved the activation of pro-apoptotic
miR-34a, dependent on FoxO3. miR-34a targeted protein
deacetylase, SIRT1, and anti-apoptotic proteins. Further,
cholangiocyte lipoapoptosis was also evident in an animal
model of NASH.
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